Differential profile analysis of urinary cytokines in patients with overactive bladder

Ghoniem, Gamal M.; Faruqui, Nuzhat; Elmissiry, Mostafa; Mahdy, Ayman; Abdelwahab, Hassan; Oommen, Mathew; Abdel-Mageed, Asim B.

doi:10.1007/s00192-011-1401-8

Cited by 71 publications

(53 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings further suggest that a preconditioned state of high inflammation may be present in some patients causing bladder pathology thus contributing to prolonged recovery of continence. Indeed our previous study leading to this investigation postulated that elevated expression of MCP-1 in patients with overactive bladder could contribute to incontinence [10]. Another important aspect of our investigation is the pinning down MCP-1/TV as a potential biomarker to identify subjects that can start medications early in the recovery process.…”

Section: Discussionmentioning

confidence: 93%

“…Currently, lack of the knowledge on the preoperative biomarkers alluding to postoperative incontinence is a limiting factor in the counseling process because the information may potentially be used as an additional component at the time of counseling. To this end, a previous study using a proteomics chip based analysis of urinary cytokine expression demonstrated that OAB group expressed Monocyte Chemotactic Protein-1 (MCP-1) two-fold higher than UTI population and controls, thus suggesting MCP-1 to be a potential target for an OAB biomarker [10]. Based on these premises, we conducted a clinical study to assess whether urinary MCP-1 can be a potential preoperative biomarker associated with the outcome of 30-day urinary continence after robotic radical prostatectomy (RRP).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Monocyte Chemotactic Protein-1 (MCP-1) as a Predictor of Prolonged Urinary Incontinence After Radical Prostatectomy

Liss¹,

Ahlering

Morales

et al. 2016

TOUNJ

View full text Add to dashboard Cite

Objectives:To investigate monocyte chemotactic protein-1 (MCP-1) as a novel urinary biomarker to predict prolonged post prostatectomy incontinence. Methods:Men submitted urine samples prior to robotic radical prostatectomy. MCP-1 values were derived using an ELISA test. Pad usage at 7, 30, and 60 days were documented by patient post cards mailed when zero pads was reached. The primary outcome was defined as no incontinence pad usage at 30 days at prostatectomy. Results:After exclusions, 76 patients were included in analyses. Continence was reached by 29% (22/76), 56% (42/76), and (75/76) 98% at 7, 30, and 60 days, respectively. The average MCP-1 (p=0.258) was not different between the continent and incontinent groups. Highest quartile of MCP-1 (MCP > 166 pg/mL) and normalized MCP-1 (MCP-1/TV >0.53) noted a significant delay in continence at 30 days (p=0.050 and p=0.003). Only 26% (5/19) in the highest MCP1/TV quartile were continent, whereas 65% (37/57) of men in the 3 lower quartiles reached zero pad continence (p=0.003). In a logistic regression model the highest quartile of MCP1/TV had a significant chance of being incontinent at 30 days (OR 0.22; 95% CI 0.058-0.80; p=0.022). Conclusion:MCP-1/TV is a urinary biomarker that may predict prolonged urinary incontinence after radical prostatectomy.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Monocyte Chemotactic Protein-1 (MCP-1) as a Predictor of Prolonged Urinary Incontinence After Radical Prostatectomy

Liss¹,

Ahlering

Morales

et al. 2016

TOUNJ

View full text Add to dashboard Cite

show abstract

“…[18], используя люминесцентный ме-тод, выявили значительное увеличение уровней моноцит-хемотаксичного протеина 1-го типа и интерлейкинов (IL-10 и IL-12) у пациентов с ГМП по сравнению с таковыми в контрольной группе. В другом исследовании обнаруже-ны повышение концентрации IL-16 и снижение IL-7 в моче у пациентов с симптомами ГМП [19].…”

Section: мочевые биомаркерыunclassified

Novelty in the diagnosis of overactive bladder

Amirova¹,

Балан²,

Kovaleva³

et al. 2015

Ross. vestn. akush.-ginekol.

View full text Add to dashboard Cite

Увеличение продолжительности жизни населения влечет за собой повышение частоты развития заболева-ний, ассоциированных с возрастом, в том числе гиперак-тивного мочевого пузыря (ГМП). По данным последних эпидемиологических исследований, распространенность симптомов ГМП составляет 7-27% среди мужчин и 9-43% среди женщин [1].Показано, что частота развития ГМП у женщин со-ставляет 20-30% в репродуктивном возрасте, 30-40% в перименопаузе и ранней постменопаузе, а в пожилом воз-расте достигает 50%. Установлено, что пациенты редко обращаются за медицинской помощью, а среди обратив-шихся только 2% получают адекватную терапию [2]. «Золотым стандартом» в диагностике ГМП и гипер-активности детрузора является комплексное уродинами-ческое исследование, однако инвазивность, трудоем-кость и дороговизна метода зачастую являются прегра-дой для масштабного скрининга населения с целью улуч-шения качества доступной медицинской помощи. Со-временные исследования посвящены определению воз-можностей использования неинвазивных биомаркеров для выявления симптомов ГМП, оценки эффективности лечения и прогнозирования исхода заболевания. Подоб-ные методики включают ультразвуковую оценку толщи-ны стенки мочевого пузыря и толщины детрузора, опре-деление параметров сывороточных (С-реактивный бе-

show abstract

“…

Dear Editor, We read with interest the recent paper by Ghoniem et al [1] exploring urinary cytokine profiles of women with overactive bladder (OAB) in comparison to both healthy controls and women with UTI. While we applaud their efforts to apply such innovative techniques, we wish to raise concerns regarding the statistical methods used to analyse data from the cytokine antibody arrays.

The authors report p values <0.05 in association with twofold overexpression for six of the cytokines assayed comparing controls and women with OAB, and for 13 of the cytokines assayed comparing controls and women with UTI.

…”

mentioning

confidence: 99%

“…Dear Editor, We read with interest the recent paper by Ghoniem et al [1] exploring urinary cytokine profiles of women with overactive bladder (OAB) in comparison to both healthy controls and women with UTI. While we applaud their efforts to apply such innovative techniques, we wish to raise concerns regarding the statistical methods used to analyse data from the cytokine antibody arrays.…”

mentioning

confidence: 99%

Differential profile analysis of urinary cytokines in patients with overactive bladder: comment

Cartwright

Khullar²,

Mangino

2012

Int Urogynecol J

View full text Add to dashboard Cite

Dear Editor, We read with interest the recent paper by Ghoniem et al. [1] exploring urinary cytokine profiles of women with overactive bladder (OAB) in comparison to both healthy controls and women with UTI. While we applaud their efforts to apply such innovative techniques, we wish to raise concerns regarding the statistical methods used to analyse data from the cytokine antibody arrays.The authors report p values <0.05 in association with twofold overexpression for six of the cytokines assayed comparing controls and women with OAB, and for 13 of the cytokines assayed comparing controls and women with UTI. Despite failing to reproduce the well-recognised association between NGF and OAB, the authors concluded that a subset of the cytokines were upregulated in both OAB and UTI.We believe that these results can more plausibly be explained by type I error. Simultaneously assaying 120 cytokines in three groups of women introduced the risk of type I error. The authors chose a significance level of 0.05, which would be expected to give 12 false positives among the 240 hypotheses they tested. As an example, using the observed mean for NGF among controls and the pooled standard deviation, and applying the conservative Bonferroni correction, we estimate the power of the study to detect a twofold change as only 14%. Even adjusting the p values, using the less conservative Benjamini and Hochberg false discovery rate method [2], suggests that the "top hits" MCP-2 and MCP-1 were no longer significantly different between controls and cases, with p00.106 and p00.364, respectively.As we increasingly see application of "'omics" technologies to urogynaecology, it is important that we consider the perils of multiple hypothesis testing. Just as in randomised interventional trials, we should expect to see careful consideration of sample size, and cautious interpretation of results that have not been replicated.

show abstract

Differential profile analysis of urinary cytokines in patients with overactive bladder

Abstract: Taken together, the results suggest that a subset of inflammatory cytokines and chemokines provides a framework for development of highly optimized urinary biomarker assay for differential diagnosis and treatment of OAB.

Cited by 71 publications

References 27 publications

Monocyte Chemotactic Protein-1 (MCP-1) as a Predictor of Prolonged Urinary Incontinence After Radical Prostatectomy

Monocyte Chemotactic Protein-1 (MCP-1) as a Predictor of Prolonged Urinary Incontinence After Radical Prostatectomy

Novelty in the diagnosis of overactive bladder

Differential profile analysis of urinary cytokines in patients with overactive bladder: comment

Contact Info

Product

Resources

About